期刊文献+

35例炎性乳腺癌的综合治疗体会 被引量:1

原文传递
导出
摘要 目的 探讨炎性乳腺癌(IBC)的临床病理特点、综合治疗疗效及预后.方法 回顾性分析35例IBC患者的临床资料.结果 35例患者中完全缓解7例,部分缓解18例,稳定7例,进展3例,总有效率为71.4%(25/35);平均生存期38.5个月,1,3,5年生存率分别为80.0%(28/35),54.3%(19/35),34.3%(12/35).结论 IBC恶性程度高,侵袭性强,预后差,应采取综合治疗.
作者 陈宏甡
出处 《中国医师进修杂志》 2014年第2期53-55,共3页 Chinese Journal of Postgraduates of Medicine
  • 相关文献

参考文献10

  • 1沈坤炜.炎性乳腺癌[J].实用癌症杂志,1998,13(2):158-160. 被引量:13
  • 2Yang WT,Le-Petross HT,Macapinlac H. Inflammatory breast cancer:PET/CT,MRI,mammography,and sonography findings[J].{H}Breast Cancer Research and Treatment,2008,(3):417-426.
  • 3汤钊猷.现代肿瘤学[M]{H}上海:上海医科大学出版社,1993675.
  • 4Anderson WF,Chu KC,Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma:distinct clinicopathologic entities[J].{H}Journal of Clinical Oncology,2003,(12):2254-2259.
  • 5L(e) MG,Arriagada R,Bahi J. Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer[J].{H}BREAST,2006,(3):355-362.
  • 6Hennessy BT,Gonzalez-Angulo AM,Hortobagyi GN. Diseasefree and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy[J].{H}CANCER,2006,(5):1000-1006.
  • 7Cristofanilli M,Valero V,Buzdar AU. Inflammatory breast cancer (IBC) and patterns of recurrence:understanding the biology of a unique disease[J].{H}CANCER,2007,(7):1436-1444.
  • 8Hurley J,Doliny P,Reis I. Docetaxel,cisplatin,and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer[J].{H}Journal of Clinical Oncology,2006,(12):1831-1838.
  • 9Gianni L,Eiermann W,Semiglazov V. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer (the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort[J].{H}LANCET,2010,(9712):377-384.
  • 10左文述;徐忠法;刘奇.现代乳腺肿瘤学[M]{H}济南:山东科学技术出版社,1996503.

共引文献12

同被引文献17

  • 1Li BD, Sicard MA, Ampil F, et al. Trimodal thera py for inflammatory breast cancer: a surgeon's perspective [J]. Oncology, 2010,79 ( 1/2 ) : 3-12.
  • 2Dawood S. Biology and management of inflammatory breast cancer [J]. Expert Rev Anticancer Ther, 2010,10(2) :209-220.
  • 3Arias-Pulido H, Chaher N, Gong Y, et al. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer[J]. BMC Cancer,2012,12:298.
  • 4Kashiwagi S, Yashiro M, Takashima T,et al. Significance of E-cadherin expression in triple-negative breast cancer [J]. Br J Cancer, 2010,103 (2) : 249-255.
  • 5Lan C, Liu JM, Liu TW,et al. Erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2+ in analysis [J]. Am J Clin Pathol, 2005,124( 1 ) :97-102.
  • 6Gong Y. Pathologic aspects of inflammatory breast cancer: part 2. Biologic insights into its aggressive phenotype [J]. Semin Oncol, 2008,35 ( 1 ) : 33-40.
  • 7Ben Hamida A, Labidi IS, Mrad K,et al. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin [ J ]. BMC Cancer, 2008,8 : 28.
  • 8Levine PH, Portera CC, Hoffman H J, et al. Evaluation oflymphangiogenic factors, vascular endothelial growth factor D and E-cadherin in distinguishing inflammatory from locally advanced breast cancer[J]. Clin Breast Cancer, 2012,12(4) :232-239.
  • 9yon Minckwitz G, Sinn HP, Raab G, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast[ J ]. Breast Cancer Res, 2008,10(2) :R30.
  • 10Aomatsu S, Abigail S, Kelly K, et al. Neoadjuvant systemic treatment of breast cancer [ J ]. J Surg Oncol, 2011,103 (4):348- 357.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部